Nature of the Event

Gland Pharma Limited has disclosed the grant of Employee Stock Options (ESOPs) under its Gland Pharma Employee Stock Option Scheme 2025 (ESOP 2025). This is a regulatory filing made to the BSE Limited and the National Stock Exchange of India Limited.

Key Quantitative Figures

  • Total number of options granted: 5,90,249 (Five Hundred Ninety Thousand Two Hundred Forty-Nine)
  • Number of employees granted options: 124 (One Hundred and Twenty-Four)
  • Breakdown of options by exercise price:
  • 3,89,564 (Three Hundred Eighty Nine Thousand Five Hundred Sixty Four) options granted at an exercise price of ₹ 1,461.15 per share
  • 2,00,685 (Two Hundred Thousand Six Hundred and Eighty-Five) options granted at an exercise price of ₹ 1 per share

Dates of Action

  • Date of Committee Meeting and Grant: September 13, 2026
  • Vesting Schedule:
  • 34% of options vest on September 13, 2027
  • 33% of options vest on September 13, 2028
  • 33% of options vest on September 13, 2029
  • Exercise Window: Options may be exercised within a maximum period of two years from their respective vesting dates.
  • Reference to previous intimations: May 15, 2026 and July 30, 2026.

Parties Involved

  • The grant was approved by the ESOP Compensation Committee of the Board of Directors of Gland Pharma Limited.
  • The disclosure is signed by Sampath Kumar Pallerlamudi, Company Secretary & Compliance Officer.
  • The recipients are 124 employees of the company.

Pricing Formula / Grant Price Rationale

  • The price of ₹ 1,461.15 for 389,564 options is set at 50% of the closing price of the company's equity share on the NSE on the date of grant.
  • Since September 13, 2026 (the grant date) was a trading holiday, the closing price from the latest preceding trading day, September 11, 2026, was considered for this calculation.
  • The price of ₹ 1 for 200,685 options is set at the face value of the equity share.

Other Disclosed Information

  • The fields for Options exercised, Money realized, Total shares from exercise, Options lapsed, Variation of terms, Subsequent changes/cancellation/exercise, and Diluted EPS are all marked as 'Not Applicable' for this grant disclosure.

Financial and Capital Structure Impact

  • The disclosure provides the number of options granted but does not quantify the potential dilution or financial impact on earnings per share upon future exercise of these options.
  • The vesting schedule is provided, but the total potential cash inflow from option exercise is not calculated or disclosed.